Skip to main content
Bio Solution Co.,Ltd. logo

Bio Solution Co.,Ltd. — Investor Relations & Filings

Ticker · 086820 ISIN · KR7086820008 KO Manufacturing
Open in API
Filings indexed 214 across all filing types
Latest filing 2025-03-05 Legal Proceedings Report
Country KR South Korea
Listing KO 086820

About Bio Solution Co.,Ltd.

https://bio-solution.co.kr/

Bio Solution Co., Ltd. is a biotechnology company focused on the development, manufacturing, and sale of cell therapy products. The company's core activities involve cell-based biotechnology, producing therapeutics such as autologous chondrocyte treatments for cartilage regeneration. In addition to its therapeutic offerings, Bio Solution develops human tissue models and provides alternative testing solutions. The company also manufactures and distributes a portfolio of bio-laboratory products, including ready-to-use kits, staining solutions, and various reagents for molecular biology research and development applications.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험결과) (카티라이프(바솔자가연골유래연골세포)의 제3상 최종 임상시험결과보고서 수령)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory filing from a Korean company (Biosolution) regarding the receipt of a final clinical trial report (Phase 3) for its product 'Cartilife'. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) as required by the Korea Exchange (KRX). Since it details the results of a clinical trial and regulatory status, it falls under the category of general regulatory announcements for material corporate events.
2025-03-05 Korean
투자판단관련주요경영사항(임상시험계획승인신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (BioSolution) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for approval of a clinical trial (IND). This type of disclosure is a standard regulatory requirement for publicly traded companies in Korea to inform investors of material business developments. Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-02-18 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (BioSolution) announcing a significant change (over 30%) in financial results (revenue, operating profit, net income) compared to the previous fiscal year. This is a standard regulatory disclosure requirement in the Korean market for listed companies to report material financial fluctuations before the final audit report is published. It fits the 'Earnings Release' (ER) category as it provides key financial highlights and the primary reason for the change, rather than being a full annual report or a simple announcement of a report's availability. FY 2024
2025-02-13 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a short announcement regarding the scheduling of an Investor Relations (IR) meeting (Non-Deal Roadshow). It provides details such as the date, location, purpose, and the method of the meeting. It does not contain the actual presentation slides or financial data, but rather serves as a notification of the event. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Regulatory Filing (RNS) when it does not fit into more specific categories like RPA (which is typically for report publication).
2025-01-23 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for the upcoming Annual General Meeting (AGM). It is not the AGM presentation itself, nor is it a proxy statement, but rather a formal notice of a corporate action (setting a record date) required by regulatory standards. Given the short length and the nature of the announcement, it fits best as a general regulatory filing.
2024-12-13 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Biosolution' (주식회사바이오솔루션) covering the period from 2024.01.01 to 2024.09.30. It contains detailed financial statements, business operations, management analysis, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.